Trials / Recruiting
RecruitingNCT03987763
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDP-122 Lotion | Topical |
Timeline
- Start date
- 2019-10-22
- Primary completion
- 2026-05-01
- Completion
- 2026-06-01
- First posted
- 2019-06-17
- Last updated
- 2025-08-27
Locations
9 sites across 3 countries: United States, Dominican Republic, Panama
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03987763. Inclusion in this directory is not an endorsement.